IP Library Granted Patent US 12,000,844
Granted Patent B2
US 12,000,844 · App. 17/265,805 · Granted Jun 4, 2024

Diagnostic drug and diagnostic method for Alzheimer's disease

Inventors: Atsushi Ono (Osaka, JP); Yasuhiro Teranishi (Osaka, JP); Masanori Kusumoto (Osaka, JP); Masakazu Hashimoto (Osaka, JP); Shoji Kashiwabara (Suita, JP); Maki Hashimoto (Suita, JP)
Assignee: SUMITOMO PHARMA CO., LTD.
G01N33/6896C07K16/18G01N33/15G01N33/531
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,000,844
App. No.
17/265,805
Granted
Jun 4, 2024
Kind
B2
Abstract

The present invention provides a polypeptide consisting of any of the following amino acid sequences and useful for determining Alzheimer's disease: (1) the amino acid sequence shown in SEQ ID NO: 1; and (2) an amino acid sequence resulting from substitution, deletion, addition or insertion of one to several amino acids in the amino acid sequence shown in SEQ ID NO: 1.

Claims (27)

1. An antibody recognizing a S38AA polypeptide, wherein the S38AA polypeptide consists of the amino acid sequence of SEQ ID NO: 1, or an amino acid sequence resulting from substitution, deletion, addition, or insertion of one to several amino acids in the amino acid sequence of SEQ ID NO: 1, and wherein the antibody is

(a) an antibody comprising the heavy chain variable region of SEQ ID NO: 4, and the light chain variable region of SEQ ID NO: 5,

(b) an antibody comprising the heavy chain variable region of SEQ ID NO: 6, and the light chain variable region of SEQ ID NO: 7,

(c) an antibody comprising the heavy chain variable region of SEQ ID NO: 8, and the light chain variable region of SEQ ID NO: 9,

(d) an antibody comprising the heavy chain variable region of SEQ ID NO: 10, and the light chain variable region of SEQ ID NO: 11,

(e) an antibody comprising the heavy chain variable region of SEQ ID NO: 12, and the light chain variable region of SEQ ID NO: 13,

(f) an antibody comprising the heavy chain variable region of SEQ ID NO: 14, and the light chain variable region of SEQ ID NO: 15,

(g) an antibody comprising the heavy chain variable region of SEQ ID NO: 16, and the light chain variable region of SEQ ID NO: 17,

(h) an antibody comprising the heavy chain variable region of SEQ ID NO: 18, and the light chain variable region of SEQ ID NO: 19,

(i) an antibody comprising the heavy chain variable region of SEQ ID NO: 20, and the light chain variable region of SEQ ID NO: 21, or

(j) an antibody comprising the heavy chain variable region of SEQ ID NO: 22, and the light chain variable region of SEQ ID NO: 23.

2. The antibody of claim 1 , further recognizing the polypeptide of SEQ ID NO: 2.

3. The antibody of claim 1 , wherein the S38AA polypeptide consists of the amino acid sequence of SEQ ID NO: 1.

4. The antibody of claim 1 , wherein the antibody is an antibody comprising the heavy chain variable region of SEQ ID NO: 4, and the light chain variable region of SEQ ID NO: 5.

5. The antibody of claim 1 , wherein the antibody is an antibody comprising the heavy chain variable region of SEQ ID NO: 6, and the light chain variable region of SEQ ID NO: 7.

6. The antibody of claim 1 , wherein the antibody is an antibody comprising the heavy chain variable region of SEQ ID NO: 8, and the light chain variable region of SEQ ID NO: 9.

7. The antibody of claim 1 , wherein the antibody is an antibody comprising the heavy chain variable region of SEQ ID NO: 10, and the light chain variable region of SEQ ID NO: 11.

8. The antibody of claim 1 , wherein the antibody is an antibody comprising the heavy chain variable region of SEQ ID NO: 12, and the light chain variable region of SEQ ID NO: 13.

9. The antibody of claim 1 , wherein the antibody is an antibody comprising the heavy chain variable region of SEQ ID NO: 14, and the light chain variable region of SEQ ID NO: 15.

10. The antibody of claim 1 , wherein the antibody is an antibody comprising the heavy chain variable region of SEQ ID NO: 16, and the light chain variable region of SEQ ID NO: 17.

11. The antibody of claim 1 , wherein the antibody is an antibody comprising the heavy chain variable region of SEQ ID NO: 18, and the light chain variable region of SEQ ID NO: 19.

12. The antibody of claim 1 , wherein the antibody is an antibody comprising the heavy chain variable region of SEQ ID NO: 20, and the light chain variable region of SEQ ID NO: 21.

13. The antibody of claim 1 , wherein the antibody is an antibody comprising the heavy chain variable region of SEQ ID NO: 22, and the light chain variable region of SEQ ID NO: 23.

14. An agent for determining Alzheimer's disease or the progression of Alzheimer's disease in a subject, comprising the antibody of claim 1 .

15. A kit comprising the antibody of claim 1 .

16. The kit of claim 15 , further comprising a S38AA polypeptide, wherein the S38AA polypeptide consists of the amino acid sequence of SEQ ID NO: 1, or an amino acid sequence resulting from substitution, deletion, addition, or insertion of one to several amino acids in the amino acid sequence of SEQ ID NO: 1.

17. A method for detecting a S38AA polypeptide, wherein the S38AA polypeptide consists of the amino acid sequence of SEQ ID NO: 1, or an amino acid sequence resulting from substitution, deletion, addition, or insertion of one to several amino acids in the amino acid sequence of SEQ ID NO: 1, which method comprises a step of contacting a test sample with the antibody of claim 1 .

Assignments (2)
NAME AND ADDRESS CHANGE Recorded May 4, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 059855/0333 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2021
From: OHNO, ATSUSHI; TERANISHI, YASUHIRO; KUSUMOTO, MASANORI; HASHIMOTO, MASAKAZU; KASHIWABARA, SHOJI; HASHIMOTO, MAKI
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 055213/0570 →
Priority Claims (1)
JP 2018-148924 · Aug 7, 2018 · national
Continuity (1)
Related Publication 20210165002A1 · Jun 3, 2021